Showing 1,181 - 1,200 results of 1,255 for search '"Zhejiang University"', query time: 0.08s Refine Results
  1. 1181
  2. 1182
  3. 1183

    Clinical Utility of the Trajectory of Serum Bilirubin and International Normalized Ratio Values in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure by Song YQ, Fu XY, Yan SY, Qi RB, Zhou YJ, Liang JW, Zhang JQ, Ye LP, Mao XL, Li SW

    Published 2025-02-01
    “…Ya-qi Song,1,2,* Xin-yu Fu,1,3,* Si-yan Yan,4 Rong-bin Qi,5 Yi-jing Zhou,1 Jia-wei Liang,6 Jin-qiu Zhang,1 Li-ping Ye,1 Xin-li Mao,1 Shao-wei Li1 1Department of Gastroenterology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, People’s Republic of China; 2Department of Gastroenterology, Taizhou Hospital of Zhejiang Province, Linhai, Zhejiang, People’s Republic of China; 3Dalian Medical University, Dalian, People’s Republic of China; 4Department of Gastroenterology, Taizhou Hospital of Zhejiang Province, Zhejiang University, Linhai, Zhejiang, People’s Republic of China; 5Department of Respiratory Medicine, TaiZhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, People’s Republic of China; 6Department of Thoracic Surgery, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xin-li Mao; Shao-wei Li, Department of Gastroenterology, Taizhou Hospital of Zhejiang Province affiliated With Wenzhou Medical University, Linhai, Zhejiang Province, People’s Republic of China, Email maoxl@enzemed.com; li_shaowei81@hotmail.comBackground and Aim: Acute-on-chronic liver failure (ACLF) is a rapidly progressive and highly fatal condition. …”
    Get full text
    Article
  4. 1184
  5. 1185
  6. 1186
  7. 1187
  8. 1188
  9. 1189
  10. 1190

    The Clinical Characteristics, Patterns of Recurrence, and Long-Term Survival Outcomes of Dual-Phenotype Hepatocellular Carcinoma After Curative Liver Resection by Yu ZC, Fang ZK, Yu Y, Liu SY, Wang KD, Shi ZJ, Jin LM, Huang XK, Lu Y, Shen GL, Liu JW, Huang DS, Zhang CW, Liang L

    Published 2025-01-01
    “…Zi-Chen Yu,1,2 Zheng-Kang Fang,1,2 Yang Yu,3 Si-Yu Liu,4 Kai-Di Wang,1,5 Zhe-Jin Shi,1,5 Li-Ming Jin,1 Xiao-Kun Huang,1,2 Yi Lu,1 Guo-Liang Shen,1 Jun-Wei Liu,1 Dong-Sheng Huang,1 Cheng-Wu Zhang,1 Lei Liang1 1Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, General Surgery, Cancer Center, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, People’s Republic of China; 2Department of Postgraduate Training Base Alliance of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 3Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 4Department of Laboratory Medicine, The Key Laboratory of Imaging Diagnosis and Minimally Invasive Interventional Research of Zhejiang Province, Zhejiang University Lishui Hospital, Lishui, Zhejiang, People’s Republic of China; 5Department of the second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People’s Republic of ChinaCorrespondence: Lei Liang, General Surgery, Cancer Center, Department of Hepatobiliary and Pancreatic Surgery and Minimal Invasive Surgery, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, People’s Republic of China, Email liangl1992@hotmail.comBackground & Aims: Dual-phenotype hepatocellular carcinoma (DPHCC) is discernible from classical HCC (CHCC) in its morphology and is characterized by the co-expression of both CHCC and cholangiocyte markers. …”
    Get full text
    Article
  11. 1191

    Global research landscape and hotspots for ferroptosis in glioma: A comprehensive bibliometric and visual analysis by Xinyue Zheng, Mengyao Diao, Shan Tong, Shuo Yang, Jing Lin, Shenghua Zhuo, Ting Wang, Jian Dai, Shenbo Chen, Kai Wang

    Published 2025-02-01
    “…Notably, Central South University, Shandong University, and Zhejiang University emerged as leaders in both literature production and research collaboration. …”
    Get full text
    Article
  12. 1192
  13. 1193
  14. 1194

    Intervening Non-Small-Cell Lung Cancer Progression by Cell Membrane Coated Platycodin D via Regulating Hsa-miR-1246/FUT9/GSK3β Pathway by Zheng S, Xie Z, Zhou Z, Wang S, Xin Y, Lin J, Cheng K, Lu T, Qi R, Guo Y

    Published 2025-02-01
    “…Shuyu Zheng,1,2 Zejuan Xie,1 Ziao Zhou,1 Shanshan Wang,1 Yanlin Xin,1 Jiamin Lin,1 Keyu Cheng,1 Tianming Lu,1 Ruogu Qi,1 Yuanyuan Guo1 1Department of Biochemistry and Molecular Biology, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, People’s Republic of China; 2Department of Neurosurgery, The Second Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang Province, 310009, People’s Republic of ChinaCorrespondence: Ruogu Qi; Yuanyuan Guo, Department of Biochemistry and Molecular Biology, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, People’s Republic of China, Email rqi@njucm.edu.cn; guoyy@njucm.edu.cnPurpose: Metastatic non-small cell lung cancer (NSCLC) remains a global health threat, with patients facing inevitable disease progression despite standard-of-care therapy. …”
    Get full text
    Article
  15. 1195
  16. 1196
  17. 1197
  18. 1198

    Co-Delivery of Dacarbazine and miRNA 34a Combinations to Synergistically Improve Malignant Melanoma Treatments by Ding B, Li M, Zhang J, Zhang X, Gao H, Gao J, Shen C, Zhou Y, Li F, Liu A

    Published 2025-01-01
    “…Baoyue Ding,1,2,* Mingjuan Li,2,* Jie Zhang,2,* Xiaojuan Zhang,2 Huan Gao,2 Jianqing Gao,3 Chunyan Shen,4 Yan Zhou,4 Fanzhu Li,5 Ailin Liu1 1Department of Pharmaceutical Analysis, Higher Educational Key Laboratory for Nano Biomedical Technology of Fujian Province, The School of Pharmacy, Fujian Medical University, Fuzhou, 350122, People’s Republic of China; 2Jiaxing Key Laboratory for Photonanomedicine and Experimental Therapeutics, Department of Pharmaceutics, Jiaxing University College of Medicine, Jiaxing, Zhejiang, People’s Republic of China; 3Institute of Pharmaceutics, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, 310058 People’s Republic of China; 4Jiaxing Institute for Food, Drug and Product Quality Control, Jiaxing, Zhejiang, People’s Republic of China; 5Zhejiang Chinese Medical University, School of Pharmaceutical Science, Hangzhou, 310053, People’s Republic of China*These authors contributed equally to this workCorrespondence: Fanzhu Li; Ailin Liu, Email lifanzhu@zcmu.edu.cn; ailinliu@mail.fjmu.edu.cnPurpose: The incidence of malignant melanoma (MM) has risen over the past three decades, and despite advancements in treatment, there is still a need to improve treatment modalities. …”
    Get full text
    Article
  19. 1199
  20. 1200